Cover Image
市場調查報告書

脂肪代謝障礙 :開發平台分析

Lipodystrophy - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 192679
出版日期 內容資訊 英文 51 Pages
訂單完成後即時交付
價格
Back to Top
脂肪代謝障礙 :開發平台分析 Lipodystrophy - Pipeline Review, H2 2016
出版日期: 2016年08月24日 內容資訊: 英文 51 Pages
簡介

所謂脂肪代謝障礙是以體脂脂的選擇性現象為特徵之脂肪組織失調。症狀有皮下脂肪流失、胰島素抗性、糖尿病、高脂值等。致病原因有HIV,肥胖,老化等。

本報告提供脂肪代謝障礙的治療藥開發平台現狀及最新更新的各開發階段比較分析,提供您企業和研究機關開發中的治療藥,治療藥評估,後期階段及中止的計劃等相關資訊。同時再加上最新的新聞和發表訊息。

簡介

  • 調查範圍

脂肪代謝障礙 概要

治療藥的開發

  • 開發中產品;概要
  • 開發中產品;比較分析

企業開發中的治療藥

開發中產品概況

  • 後期階段的產品
  • 臨床實驗階段的產品
  • 初期階段的產品

企業開發中的產品

治療藥的開發企業

  • Aegerion Pharmaceuticals, Inc.
  • Ambrx, Inc.
  • Bolder Biotechnology, Inc.
  • Galmed Pharmaceuticals Ltd.
  • Theratechnologies Inc.
  • Zydus Cadila Healthcare Limited

治療藥的評估

  • 單劑產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

  • Aramchol
  • ARX-328
  • BBT-031
  • metreleptin
  • saroglitazar
  • tesamorelin acetate
  • volanesorsen sodium

最近的開發平台趨勢

暫停中的計劃

產品開發的里程碑

  • 主要消息和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8394IDB

Summary

Global Markets Direct's, 'Lipodystrophy - Pipeline Review, H2 2016', provides an overview of the Lipodystrophy pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Lipodystrophy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Lipodystrophy and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Lipodystrophy
  • The report reviews pipeline therapeutics for Lipodystrophy by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Lipodystrophy therapeutics and enlists all their major and minor projects
  • The report assesses Lipodystrophy therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Lipodystrophy

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Lipodystrophy
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Lipodystrophy pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Lipodystrophy Overview
  • Therapeutics Development
    • Pipeline Products for Lipodystrophy - Overview
  • Lipodystrophy - Therapeutics under Development by Companies
  • Lipodystrophy - Pipeline Products Glance
    • Late Stage Products
    • Early Stage Products
  • Lipodystrophy - Products under Development by Companies
  • Lipodystrophy - Companies Involved in Therapeutics Development
    • Aegerion Pharmaceuticals, Inc.
    • Akcea Therapeutics Inc
    • Ambrx, Inc.
    • Amunix Operating Inc.
    • Bolder Biotechnology, Inc.
  • Lipodystrophy - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • AMX-342 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ARX-328 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BBT-031 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • metreleptin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • volanesorsen sodium - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Lipodystrophy - Product Development Milestones
    • Featured News & Press Releases
      • Jul 28, 2016: Akcea Therapeutics Receives Orphan Designation in Europe for Volanesorsen for the Treatment of Familial Partial Lipodystrophy
      • Jun 27, 2016: Akcea Announces Publication of Positive Volanesorsen Clinical Data Showing Reduced Triglycerides and Improved Insulin Sensitivity in Patients with High Triglycerides and Type 2 Diabetes
      • May 29, 2014: Zydus Explores Newer Treatment Options With its Breakthrough Drug, Lipaglyn
      • Feb 25, 2014: FDA approves Myalept to treat rare metabolic disease
      • Dec 12, 2013: FDA Advisory Committee votes on investigational medicine metreleptin
      • Jun 04, 2013: Bristol-Myers Squibb And AstraZeneca Receive FDA Priority Review Designation For Metreleptin
      • May 06, 2013: Bristol-Myers Squibb And AstraZeneca Announce Positive Results From Sub-Group Analysis Of Metreleptin In Pediatric Patients With Lipodystrophy
      • Aug 01, 2012: Shionogi Files New Drug Application For Recombinant Human Leptin For Lipodystrophy
      • Jun 25, 2012: New Clinical Data Analyses Show Amylin Pharma's Metreleptin Reduced Blood Glucose And Triglyceride Levels In Patients With Rare Forms Of Lipodystrophy
      • Apr 03, 2012: Amylin Completes Biologics License Application For Metreleptin To Treat Diabetes And/Or Hypertriglyceridemia In Patients With Rare Forms Of Lipodystrophy
      • Jun 04, 2011: Amylin's Study Results Show Treatment With Metreleptin Improves Diabetes And Lipid Control In Patients With Partial Lipodystrophy
      • Apr 15, 2011: Amylin To Present Data Showing Investigational Metreleptin Treatment Led To Long-Term Improvements In Diabetes And Lipid Control In Patients With Lipodystrophy
      • Dec 20, 2010: Amylin Submits Clinical And Nonclinical Sections Of Rolling Biologics License Application For Metreleptin To Treat Rare Forms Of Lipodystrophy
      • Nov 03, 2010: Bolder BioTechnology Announces $1.2 Million in Qualifying Therapeutic Discovery Project Grants
      • Dec 16, 2008: Bolder BioTechnology Receives $1.9 million NIH Grant To Continue Development of Long-Acting Growth Hormone Product BBT-031
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Lipodystrophy, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Lipodystrophy - Pipeline by Aegerion Pharmaceuticals, Inc., H2 2016
  • Lipodystrophy - Pipeline by Akcea Therapeutics Inc, H2 2016
  • Lipodystrophy - Pipeline by Ambrx, Inc., H2 2016
  • Lipodystrophy - Pipeline by Amunix Operating Inc. , H2 2016
  • Lipodystrophy - Pipeline by Bolder Biotechnology, Inc., H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016

List of Figures

  • Number of Products under Development for Lipodystrophy, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Targets, H2 2016
  • Number of Products by Stage and Targets, H2 2016
  • Number of Products by Mechanism of Actions, H2 2016
  • Number of Products by Stage and Mechanism of Actions, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top